CER Daily Newsfeed

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

(11/19, Jordyn Sava, The American Journal of Managed Care) reports “The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The investigational arm demonstrated superior progression-free survival and overall response rates, despite higher adverse event rates.” Full

With RFK Jr. Looming as Health Secretary, Pharma Execs Try to Project Stability

(11/19, Andrew Joseph, STAT Plus) reports “...Overall, the incoming Trump administration will likely be friendly to corporate interests, as the first Trump presidency was. Vivek Ramaswamy, a biotech veteran who has his own views on changing how the Food and Drug Administration regulates medicines, is also a close Trump adviser. Some pharma executives, when asked about Trump winning another term, have said they worked well with the first Trump administration.” Subscription Required

Prior Authorization Is Changing. Providers Say It's Not Enough

(11/20, Bridget Early, Modern Healthcare) reports “...CMS proposed a rule that would have required providers and insurers to use a specific set of electronic data-sharing standards for prior authorizations, claims reviews and electronic attachments. But AHIP, the American Hospital Association, American Medical Association, and the Blue Cross Blue Shield Association jointly called on CMS to rethink its proposals, which they said would create a mismatch between two regulations and worsen interoperability problems rather than fixing them.” Subscription Required